Insights On Enterprise Solutions

  1. Manufacturing Re-Engineered: Unlocking Global Access & Scale Out Economics 8/11/2026

    Transitioning from rigid, manual cell therapy processes to open, configurable automation helps streamline cleanroom operations, reduce manufacturing costs, and expand global patient access.

  2. From DNA To IND In 6 Months: Accelerated Development Backed By Experience 8/10/2026

    A rapid, integrated biologics development strategy can achieve IND readiness in as little as six months by combining parallel workflows, early risk mitigation, advanced technologies, robust analytics, and regulatory planning.

  3. Top 10 Things We Wish We'd Known Earlier In Our Biopharma Careers 8/7/2026

    Ten hard-won lessons from seasoned biopharma professionals cover the foundational habits, verification steps, and process controls that protect batch integrity and prevent costly deviations.

  4. Resilience Capabilities Update July 2026: Fill/Finish 8/7/2026

    Learn how expanding capacity, automation, and flexible manufacturing technologies are helping biologics manufacturers meet evolving market and quality demands.

  5. Rentschler Biopharma Capabilities Update July 2026: Large Molecule 8/7/2026

    At Rentschler Biopharma, we help biopharma innovators advance complex large molecule programs from development through commercial manufacturing.

  6. FUJIFILM Biotechnologies Capabilities Update July 2026: Gene Therapy 8/7/2026

    From process development to GMP manufacturing, our teams operate as one connected system to support your cell or gene therapy through every milestone.

  7. Avid Bioservices Capabilities Update July 2026: Large Molecule 8/7/2026

    Discover how integrated development and manufacturing can reduce risk, speed timelines, and support seamless progression from early development to commercial production.

  8. Built For Growth: Engineering Flexible And Scalable Bioprocessing Strategies 8/6/2026

    Standardizing bioprocess platforms and automation logic simplifies cross-site tech transfer and mitigates workforce constraints during program scale-up.

  9. Building Late-Stage Efficiency Into Biologics Development 8/6/2026

    Building late-stage efficiency early in biologics development prevents scale-up delays. Flexible platforms and risk-based validation streamline technology transfer and lower production costs.

  10. Samsung Biologics Capabilities Update July 2026: Large Molecule 8/6/2026

    We offer end-to-end CDMO services across drug substance, drug product, ADC, mRNA, and organoid modalities, with 845,000L capacity and a 99% batch success rate. Evaluate your multi-plant sourcing framework now.